Inflammatory Indices and MAFLD Prevalence in Hypertensive Patients: A Large-Scale Cross-Sectional Analysis from China

Journal of Inflammation Research, Год журнала: 2025, Номер Volume 18, С. 1623 - 1638

Опубликована: Фев. 1, 2025

Objective: Hypertension development and progression are largely influenced by inflammation, which plays a critical role activating the immune system causing damage to vascular endothelium. Metabolic dysfunction-associated fatty liver disease (MAFLD) is also associated with chronic low-grade drives via metabolic imbalances adipose tissue dysfunction. This study investigates relationship between inflammatory indices MAFLD in hypertensive patients assesses predictive accuracy of these for MAFLD. Methods: We performed cross-sectional analysis involving 34,303 from Chinese hospital-based registry. The diagnosis was established using dysfunction criteria alongside evidence hepatic steatosis confirmed through imaging. Complete blood counts were used calculate indices, including monocyte-to-lymphocyte ratio (MLR), neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR), systemic response index (SIRI), immune-inflammation (SII), aggregate inflammation (AISI). To assess MAFLD, multivariable logistic regression adjustments potential confounders. diagnostic performance analyzed receiver operating characteristic (ROC) curves area under curve (AUC) calculations. Results: Patients exhibited significantly elevated levels all compared those without. After adjustment, each standard deviation increase AISI, SIRI, SII 74%, 62%, 58% increased odds respectively. AUC AISI 0.659, indicating moderate accuracy. AUCs SIRI 0.626 0.619, respectively, while NLR, PLR, MLR had lower 0.593, 0.558, 0.589, Conclusion: In patients, especially show strong association their utility risk stratification within clinical settings. Further research needed evaluate effectiveness markers management Keywords: metabolic-dysfunction-associated disease, hypertension,

Язык: Английский

---

Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B

Hepatology International, Год журнала: 2023, Номер 17(5), С. 1139 - 1149

Опубликована: Май 29, 2023

Язык: Английский

---

Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion

Clinical Gastroenterology and Hepatology, Год журнала: 2023, Номер 22(3), С. 581 - 590.e6

Опубликована: Окт. 21, 2023

Язык: Английский

---

Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC

Clinical Gastroenterology and Hepatology, Год журнала: 2024, Номер 22(6), С. 1275 - 1285.e2

Опубликована: Фев. 15, 2024

Язык: Английский

---

Safety of tenofovir alafenamide in the context of hyperlipidemia and cardiovascular diseases: a nationwide analysis

Hepatology International, Год журнала: 2025, Номер unknown

Опубликована: Март 8, 2025

Язык: Английский

---

Hepatitis B virus infection and metabolic dysfunction associated steatotic liver disease: Rising pandemic with complex interaction

World Journal of Hepatology, Год журнала: 2025, Номер 17(1)

Опубликована: Янв. 6, 2025

Due to sedentary lifestyle and rising prevalence of obesity, patients with general population those who are infected chronic hepatitis B found have metabolic dysfunction associated steatotic liver disease (MASLD). Both virus (HBV) infection MASLD can damage hepatocytes in their own way, but concomitant HBV-MASLD has its clinical implications. Cherry on top is the presence diabetes mellitus, hypertension or obesity which added more chances unfavorable outcomes these patients. In this article, we comment article by Wang et al published recent issue. This provides a comprehensive overview complex interaction between HBV-MASLD, HBV alone We discuss key findings from studies, including promising observed concurrent MASLD, warrants further research. The insights presented here offer renewed understanding interaction.

Язык: Английский

---

Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma

Cells, Год журнала: 2025, Номер 14(6), С. 428 - 428

Опубликована: Март 13, 2025

Hepatocellular carcinoma (HCC) is the sixth most common cancer and third leading cause of deaths worldwide. The etiology HCC has now dramatically changed from viral hepatitis to metabolic dysfunction-associated steatotic liver disease (MASLD). main pathogenesis MASLD-related hepatic lipid accumulation hepatocytes, which causes chronic inflammation subsequent progression fibrosis. Chronic generates oxidative stress DNA damage in contribute genomic instability, resulting development HCC. Several molecular pathways are also linked MASLD. In particular, MAPK PI3K-Akt-mTOR upregulated MASLD, promoting survival proliferation cells. addition, MASLD been reported enhance patients with infection. Although there no approved medication for besides resmetirom USA, some preventive strategies onset Sodium-glucose cotransporter-2 (SGLT2) inhibitor, a class medications, exert anti-tumor effects on by regulating reprogramming. Moreover, CD34-positive cell transplantation improves fibrosis intrahepatic angiogenesis supplying various growth factors. Furthermore, exercise through an increase energy consumption as well changes chemokines myokines. this review, we summarize recent progress made pathogenic mechanisms MASLD-associated introduced new therapeutic preventing based

Язык: Английский

---

All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease

Journal of Hepatology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 1, 2024

Язык: Английский

---

Molecular Mechanisms of Pyroptosis in Non-alcoholic Steatohepatitis and Feasible Diagnosis and Treatment Strategies

Pharmacological Research, Год журнала: 2025, Номер unknown, С. 107754 - 107754

Опубликована: Апрель 1, 2025

Pyroptosis is a distinct form of cell death that plays critical role in intensifying inflammatory responses. It primarily occurs via the classical pathway, non-classical caspase-3/6/7/8/9-mediated pathways, and granzyme-mediated pathways. Key effector proteins involved pyroptosis process include gasdermin family pannexin-1 protein. intricately linked to onset progression non-alcoholic steatohepatitis (NASH). During development NASH, factors such as pyroptosis, innate immunity, lipotoxicity, endoplasmic reticulum stress, gut microbiota imbalance interact interweave, collectively driving disease progression. This review analyzes molecular mechanisms its pathogenesis NASH. Furthermore, it explores potential diagnostic therapeutic strategies targeting offering new avenues for improving diagnosis treatment

Язык: Английский

---

Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients

International Journal of Cancer, Год журнала: 2023, Номер 153(8), С. 1448 - 1458

Опубликована: Июль 13, 2023

Metabolic dysfunction-associated fatty liver disease (MAFLD) can coexist with chronic viral hepatitis. MAFLD is a heterogeneous because the diagnostic criteria include various metabolic traits. We aimed to identify patients at high risk of poor long-term outcomes based on subgroups in hepatitis patients. evaluated 63 273 B and C Patient index ≥30 was defined have hepatic steatosis. as presence steatosis any one following three conditions, overweight/obesity, type 2 diabetes or ≥2 factors. The prevalence 38.4% (n = 24 290). During median 8.8-year follow-up, 1839 HCCs 2258 deaths were documented Among patients, could HCC mortality, whereas overweight/obesity factors did not. Compared non-MAFLD mortality significantly higher diabetic (adjusted hazard ratio [aHR] 1.34, 95% confidence interval [CI] 1.26-1.43 for HCC; aHR 1.15, CI 1.08-1.22 mortality). Risk (aHR 1.40, 1.26-1.55 1.77, 1.63-1.93 mortality) compared non-diabetic Diabetic associated increased among Our findings highlight need close surveillance effective treatment these high-risk reduce

Язык: Английский

---